Florida Senate - 2023                                    SB 1434
       
       
        
       By Senator Simon
       
       
       
       
       
       3-01928A-23                                           20231434__
    1                        A bill to be entitled                      
    2         An act relating to prior authorization; amending s.
    3         627.42392, F.S.; defining terms; redefining the term
    4         “health insurer” as “utilization review entity” and
    5         revising the definition; requiring utilization review
    6         entities to establish and offer a prior authorization
    7         process for accepting electronic prior authorization
    8         requests; specifying a requirement for the process;
    9         specifying additional requirements and procedures for,
   10         and restrictions and limitations on, utilization
   11         review entities relating to prior authorization for
   12         covered health care benefits; defining the term
   13         “medications for opioid use disorder”; providing
   14         construction; making technical changes; providing an
   15         effective date.
   16          
   17  Be It Enacted by the Legislature of the State of Florida:
   18  
   19         Section 1. Section 627.42392, Florida Statutes, is amended
   20  to read:
   21         627.42392 Prior authorization.—
   22         (1) As used in this section, the term:
   23         (a)“Adverse determination” means a decision by a
   24  utilization review entity that the health care services
   25  furnished or proposed to be furnished to an insured are not
   26  medically necessary or are experimental or investigational, and
   27  benefit coverage is therefore denied, reduced, or terminated. A
   28  decision to deny, reduce, or terminate services that are not
   29  covered for reasons other than their medical necessity or
   30  experimental or investigational nature is not an adverse
   31  determination for purposes of this section.
   32         (b)“Electronic prior authorization process” does not
   33  include transmissions through a facsimile machine.
   34         (c)“Emergency health care services” has the same meaning
   35  as “emergency services and care” as defined in s. 395.002(9).
   36         (d)“Prior authorization” means the process by which a
   37  utilization review entity determines the medical necessity or
   38  appropriateness, or both, of otherwise covered health care
   39  services before the rendering of such health care services. The
   40  term also includes any utilization review entity’s requirement
   41  that an insured or health care provider notify the utilization
   42  review entity before providing a health care service.
   43         (e)“Urgent health care service” means a health care
   44  service that, if the timeframe for making a nonexpedited prior
   45  authorization is applied, in the opinion of a physician with
   46  knowledge of the patient’s medical condition, could:
   47         1.Seriously jeopardize the life or health of the patient
   48  or the ability of the patient to regain maximum function; or
   49         2.Subject the patient to severe pain that cannot be
   50  adequately managed without the care, treatment, or prescription
   51  drug that is the subject of the prior authorization request.
   52         (f)“Utilization review entity” “health insurer” means an
   53  authorized insurer offering health insurance as defined in s.
   54  624.603, a managed care plan as defined in s. 409.962(10), or a
   55  health maintenance organization as defined in s. 641.19(12), a
   56  pharmacy benefit manager as defined in s. 624.490, or any other
   57  individual or entity that provides, offers to provide, or
   58  administers hospital, outpatient, medical, prescription drug, or
   59  other health benefits under a policy, plan, or contract to a
   60  person treated by a health care professional in this state.
   61         (2) Beginning January 1, 2024, a utilization review entity
   62  must establish and offer a secure, interactive online electronic
   63  prior authorization process for accepting electronic prior
   64  authorization requests. The process must allow a person seeking
   65  prior authorization the ability to upload documentation if such
   66  documentation is required by the utilization review entity to
   67  adjudicate the prior authorization request.
   68         (3) Notwithstanding any other provision of law, effective
   69  January 1, 2017, or six (6) months after the effective date of
   70  the rule adopting the prior authorization form, whichever is
   71  later, a utilization review entity that health insurer, or a
   72  pharmacy benefits manager on behalf of the health insurer, which
   73  does not provide an electronic prior authorization process for
   74  use by its contracted providers, shall use only use the prior
   75  authorization form that has been approved by the Financial
   76  Services commission for granting a prior authorization for a
   77  medical procedure, course of treatment, or prescription drug
   78  benefit. Such form may not exceed two pages in length, excluding
   79  any instructions or guiding documentation, and must include all
   80  clinical documentation necessary for the utilization review
   81  entity health insurer to make a decision. At a minimum, the form
   82  must include:
   83         (a)(1) Sufficient patient information to identify the
   84  member, date of birth, full name, and health plan ID number;
   85         (b)(2)The provider’s provider name, address, and phone
   86  number;
   87         (c)(3) The medical procedure, course of treatment, or
   88  prescription drug benefit being requested, including the medical
   89  reason therefor, and all services tried and failed;
   90         (d)(4) Any laboratory documentation required; and
   91         (e)(5) An attestation that all information provided is true
   92  and accurate.
   93         (4)(3) The Financial Services commission, in consultation
   94  with the Agency for Health Care Administration, shall adopt by
   95  rule guidelines for all prior authorization forms which ensure
   96  the general uniformity of such forms.
   97         (5)(4) Electronic prior authorization approvals do not
   98  preclude benefit verification or medical review by the
   99  utilization review entity insurer under either the medical or
  100  pharmacy benefits.
  101         (6)A utilization review entity’s prior authorization
  102  process may not require information that is not needed to make a
  103  determination or facilitate a determination of medical necessity
  104  of the requested medical procedure, course of treatment, or
  105  prescription drug benefit.
  106         (7)A utilization review entity shall disclose all of its
  107  prior authorization requirements and restrictions, including any
  108  written clinical criteria, in a publicly accessible manner on
  109  its website. Such information must be explained in detail and in
  110  clear and ordinary terms.
  111         (8)A utilization review entity may not implement any new
  112  requirement or restriction or make changes to existing
  113  requirements or restrictions on obtaining prior authorization
  114  unless:
  115         (a)The changes have been available on a publicly
  116  accessible website for at least 60 days before they are
  117  implemented; and
  118         (b)Insureds and health care providers affected by the new
  119  requirements and restrictions or by the changes to the
  120  requirements and restrictions are provided with a written notice
  121  of the changes at least 60 days before they are implemented.
  122  Such notice must be delivered electronically or by other means
  123  as agreed to by the insured or the health care provider.
  124         (9)A utilization review entity shall make available data
  125  regarding prior authorization approvals and denials on its
  126  website in a readily accessible format, which must include
  127  categories specifying:
  128         (a)Physician specialty;
  129         (b)Medication or diagnostic test or procedure;
  130         (c)The indication offered;
  131         (d)The reason for denial, if applicable;
  132         (e)If denied, whether the denial was appealed;
  133         (f)If a denial was appealed, whether it was approved or
  134  denied on appeal; and
  135         (g)The time between submission and the response.
  136  
  137  This subsection does not apply to the expansion of health care
  138  services coverage.
  139         (10)A utilization review entity shall ensure that all
  140  adverse determinations are made by a physician licensed pursuant
  141  to chapter 458 or chapter 459. The physician must:
  142         (a)Possess a current and valid nonrestricted license to
  143  practice medicine in this state;
  144         (b)Be of the same specialty as the physician who typically
  145  manages the medical condition or disease or who provides the
  146  health care service involved in the request; and
  147         (c)Have experience treating patients with the medical
  148  condition or disease for which the health care service is being
  149  requested.
  150         (11)Notice of an adverse determination must be provided by
  151  e-mail to the health care provider that initiated the prior
  152  authorization. The notice must include:
  153         (a)The name, title, e-mail address, and telephone number
  154  of the physician responsible for making the adverse
  155  determination;
  156         (b)The written clinical criteria, if any, and any internal
  157  rule, guideline, or protocol the utilization review entity
  158  relied upon in making the adverse determination, and how those
  159  provisions apply to the insured’s specific medical circumstance;
  160         (c)Information for the insured and the insured’s health
  161  care provider which describes the procedure through which the
  162  insured or health care provider may request a copy of any report
  163  developed by personnel performing the review that led to the
  164  adverse determination; and
  165         (d)An explanation to the insured and the insured’s health
  166  care provider on how to appeal the adverse determination.
  167         (12)If a utilization review entity requires prior
  168  authorization of a nonurgent health care service, the
  169  utilization review entity must make an authorization or adverse
  170  determination and notify the insured and the insured’s provider
  171  of such service of the decision within 2 business days after
  172  obtaining all necessary information to make the authorization or
  173  adverse determination. For purposes of this subsection,
  174  necessary information includes the results of any face-to-face
  175  clinical evaluation or second opinion that may be required.
  176         (13)A utilization review entity shall render an expedited
  177  authorization or adverse determination concerning an urgent
  178  health care service and notify the insured and the insured’s
  179  provider of such service of the expedited prior authorization or
  180  adverse determination no later than 1 business day after
  181  receiving all information needed to complete the review of the
  182  requested urgent health care service.
  183         (14)A utilization review entity may not require prior
  184  authorization for prehospital transportation or for provision of
  185  an emergency health care service.
  186         (15)A utilization review entity may not require prior
  187  authorization for the provision of medications for opioid use
  188  disorder. As used in this subsection, the term “medications for
  189  opioid use disorder” means the use of medications approved by
  190  the United States Food and Drug Administration (FDA), commonly
  191  in combination with counseling and behavioral therapies, to
  192  provide a comprehensive approach to the treatment of opioid use
  193  disorder. Such FDA-approved medications used to treat opioid
  194  addiction include, but are not limited to, methadone;
  195  buprenorphine, alone or in combination with naloxone; and
  196  extended-release injectable naltrexone. Such types of behavioral
  197  therapies include, but are not limited to, individual therapy,
  198  group counseling, family behavior therapy, motivational
  199  incentives, and other modalities.
  200         (16)A utilization review entity may not revoke, limit,
  201  condition, or restrict a prior authorization if care is provided
  202  within 45 business days after the date the health care provider
  203  received the prior authorization. A utilization review entity
  204  shall pay the health care provider at the contracted payment
  205  rate for a health care service provided by the health care
  206  provider per a prior authorization unless:
  207         (a)The health care provider knowingly and materially
  208  misrepresented the health care service in the prior
  209  authorization request with the specific intent to deceive and
  210  obtain an unlawful payment from the utilization review entity;
  211         (b)The health care service was no longer a covered benefit
  212  on the day it was provided, and the utilization review entity
  213  notified the health care provider in writing of this fact before
  214  the health care service was provided;
  215         (c)The health care provider was no longer contracted with
  216  the insured’s health insurance plan on the date the care was
  217  provided, and the utilization review entity notified the health
  218  care provider in writing of this fact before the health care
  219  service was provided;
  220         (d)The health care provider failed to meet the utilization
  221  review entity’s timely filing requirements;
  222         (e)The authorized service was never performed; or
  223         (f)The insured was no longer eligible for health care
  224  coverage on the day the care was provided and the utilization
  225  review entity notified the health care provider in writing of
  226  this fact before the health care service was provided.
  227         (17)If a utilization review entity required a prior
  228  authorization for a health care service for the treatment of a
  229  chronic or long-term care condition, the prior authorization
  230  shall remain valid for the length of the treatment and the
  231  utilization review entity may not require the insured to obtain
  232  a prior authorization again for the health care service.
  233         (18)A utilization review entity may not impose an
  234  additional prior authorization requirement with respect to a
  235  surgical or otherwise invasive procedure, or any item furnished
  236  as part of the surgical or invasive procedure, if the procedure
  237  or item is furnished during the perioperative period of another
  238  procedure for which prior authorization was granted by the
  239  utilization review entity.
  240         (19)If there is a change in coverage or approval criteria
  241  for a previously authorized health care service, the change in
  242  coverage or approval criteria may not affect an insured who
  243  received prior authorization before the effective date of the
  244  change for the remainder of the insured’s plan year.
  245         (20)A utilization review entity shall continue to honor a
  246  prior authorization it has granted to an insured when the
  247  insured changes products under the same carrier.
  248         (21)Any failure by a utilization review entity to comply
  249  with the deadlines and other requirements specified in this
  250  section shall result in any health care services subject to
  251  review to be automatically deemed authorized by the utilization
  252  review entity.
  253         (22)The provisions of this section cannot be waived by
  254  contract. Any contractual arrangement or action taken in
  255  conflict with this section or that purports to waive any
  256  requirement of this section is void.
  257         Section 2. This act shall take effect July 1, 2023.